韩国非结核分枝杆菌感染的死亡率与预后因素:基于人群的比较研究
该研究基于韩国2002–2017年全国医保与统计数据库,将183 267例NTM感染患者与166 666例结核患者及180 468例一般人群对照进行一比一匹配,比较长期死亡率并分析相关因素。NTM组6年、10年、14年累积生存率分别为86.3%、80.8%、77.1%,显著低于结核组和对照组;NTM与结核共感染时生存率更低。大环内酯类药物使用超过1年与死亡率降低相关。
要点
- NTM感染患者长期生存率显著低于结核患者和一般人群。
- NTM与结核共感染患者预后更差,14年生存率仅57.0%。
- 长期使用大环内酯类药物(超过1年)与死亡率降低相关。
核心结论
- NTM感染患者与结核患者或一般人群相比预后较差,尤其是NTM与结核共感染患者。
- NTM死亡率与某些人口学特征相关,但长期使用大环内酯类药物可能带来生存获益。
研究设计与样本
- 基于韩国国民健康保险和韩国统计办公室2002–2017年全国性数据的比较研究。
- 共分析530 401人,包括183 267例NTM感染、166 666例结核和180 468例对照,采用一比一匹配。
主要发现
- NTM组总体6年、10年、14年累积生存概率分别为86.3%、80.8%、77.1%,显著低于结核组或对照组(log-rank P < .0001)。
- NTM与结核共感染病例的6年、10年、14年累积生存概率分别为75.1%、65.4%、57.0%。
- 多变量分析显示高龄、男性、省份以及多种呼吸或非呼吸合并症与NTM感染死亡率显著相关。
- 使用大环内酯类药物超过1年与NTM感染死亡率呈负相关(调整风险比[aHR] 0.61,95%置信区间[CI] .53-.71),无论是阿奇霉素(aHR 0.60,95% CI .43-.85)还是克拉霉素(aHR 0.63,95% CI .53-.75)。
临床怎么用
- 应关注NTM感染患者的长期生存预后,尤其对合并结核感染患者加强管理。
- 对符合条件者考虑长期使用大环内酯类药物以改善生存,需结合合并症和人口学因素个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Population-based studies on the mortality burden of nontuberculous mycobacteria (NTM) infection are lacking. We compared the long-term mortality of NTM-infected patients with tuberculosis (TB)-patients and the general population, and investigated mortality-associated factors. METHODS: We analyzed nationwide-data from the Korean National Health Insurance and Korea-Statistical Office between 2002 and 2017. NTM infection was identified using the International Classification of Disease, Tenth Revision code, with one-to-one matching to TB patients and general population controls. RESULTS: A total of 530 401 individuals were analyzed, including 183 267 with NTM infections; 166 666 with TB; and 180 468 controls. The overall 6-, 10-, and 14-year cumulative survival probabilities in the NTM group were 86.3%, 80.8%, and 77.1%, respectively, which were significantly lower than those of the TB or control groups (log-rank P < .0001). In cases of NTM and TB coinfection, the overall 6-, 10-, and 14-year cumulative survival probabilities were 75.1%, 65.4%, and 57.0%, respectively. Multivariable analysis indicated that old age, male gender, province, and various respiratory or nonrespiratory comorbidities were significantly associated with mortality of NTM infection. The use of a macrolide (more than 1 year) negatively correlated with mortality of NTM infection (adjusted hazard ratio [aHR] 0.61, 95% confidence interval [CI] .53-.71), regardless of azithromycin (aHR 0.60, 95% CI .43-.85) or clarithromycin use (aHR 0.63, 95% CI .53-.75). CONCLUSIONS: NTM-infected patients had poor prognosis when compared to TB patients or the general population, especially for NTM and TB coinfection. NTM mortality was associated with certain demographic characteristics, but long-term use of macrolides may provide survival benefits.
引用
- Lee H, Myung W, Lee EM, et al. Mortality and Prognostic Factors of Nontuberculous Mycobacterial Infection in Korea: A Population-based Comparative Study. Clin Infect Dis. 2021. PMID: 32926135. doi:10.1093/cid/ciaa1381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。